{
    "nctId": "NCT04011085",
    "briefTitle": "Tw HER2 Positive Breast Cancer Productivity & Utility Study",
    "officialTitle": "Tw HER2 Positive Breast Cancer Productivity & Utility Study",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "Work Productivity and Activity Impairment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged 18 years or over;\n* Diagnosed with early stage or metastatic (Stage IV) HER2-positive breast cancer (confirmed by the study site physician). \\[HER2-positive is defined as IHC3+ and/or ISH\u22652.0\\]\n* eBC patients should have received at least 2 cycles of adjuvant anti-cancer therapy following surgery at time of interview; metastasis breast cancer (mBC) patients should have received at least 1 cycle of treatment for their metastatic disease at time of interview.\n* Able to provide written, informed consent.\n\nExclusion Criteria:\n\n* Patients with ECOG performance status (PS) \u22653\n* Unwilling or unable to provide written, informed consent\n* Unable to complete written quality of life questionnaires",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}